The Politics of Personalised Medicine: Pharmacogenetics in the Clinic

Pharmacogenetics, the use of genetic testing to prescribe and develop drugs, has been hailed as a revolutionary development for the pharmaceutical industry and modern medicine. Supporters of 'personalised medicine' claim the result will be safer, cheaper, more effective drugs, and their arguments are beginning to influence policy debates. Based on interviews with clinicians, researchers, regulators and company representatives, this book explores the impact of pharmacogenetics on clinical practice, following two cases of personalised medicine as they make their way from the laboratory to the clinic. It highlights the significant differences between the views of supporters of pharmacogenetics in industry and those who use the technology at the clinical 'coal face'. Theoretically, this work builds on the developing area of the sociology of socio-technical expectations, highlighting the way in which promoters of new technologies build expectations around it, through citation and the creation of technological visions.

[1]  Allen D. Roses,et al.  Genome-based pharmacogenetics and the pharmaceutical industry , 2002, Nature Reviews Drug Discovery.

[2]  M. Pirmohamed,et al.  Adverse drug reactions: back to the future. , 2003, British journal of clinical pharmacology.

[3]  S. Epstein Impure Science: AIDS, Activism, and the Politics of Knowledge , 1998 .

[4]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[5]  Paul Martin,et al.  Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease , 1999 .

[6]  J. Cummings Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[7]  A. Roses Genetic testing for Alzheimer disease. Practical and ethical issues. , 1997, Archives of neurology.

[8]  Laszlo T Vaszar,et al.  Privacy issues in personalized medicine. , 2003, Pharmacogenomics.

[9]  W. Evans,et al.  Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.

[10]  K. Lindpaintner Pharmacogenetics: A New – or not so New?—Concept in Healthcare , 2003 .

[11]  H. Brown Does hope match the hype for targeted drugs? , 2003, The Lancet. Oncology.

[12]  M. Rodwin,et al.  The Politics of Evidence-Based Medicine , 2001, Journal of health politics, policy and law.

[13]  D. Roden,et al.  The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.

[14]  J. Speyer Cardiac dysfunction in the trastuzumab clinical experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Relman,et al.  America's other drug problem: how the drug industry distorts medicine and politics. , 2002, New republic.

[16]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Newman,et al.  Genetic Screening for Alzheimer's Disease: What Factors Predict Intentions to Take a Test? , 2001, Behavioral medicine.

[18]  P. Rioux Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  E. Copson,et al.  Herceptin (trastuzamab) in advanced breast cancer. , 2000, Cancer treatment reviews.

[20]  J. Poirier,et al.  Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a , 1996, Annals of the New York Academy of Sciences.

[21]  P. Ma,et al.  Oncology's trials , 2003, Nature Reviews Drug Discovery.

[22]  L. Tan,et al.  Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[23]  S. Lauri,et al.  Cancer patients' decision-making regarding treatment and nursing care. , 2003, Journal of advanced nursing.

[24]  S. Harrison THE POLITICS OF EVIDENCE-BASED MEDICINE IN THE UNITED KINGDOM , 1998 .

[25]  J. Murray,et al.  Monoclonal antibody therapy for solid tumors. , 2000, Cancer treatment reviews.

[26]  S. Perry,et al.  The NIH Consensus Development Program , 1987 .

[27]  S. Reis,et al.  Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. , 2000, Circulation.

[28]  C. Moyses Pharmacogenetics, genomics, proteomics : the new frontiers in drug development , 1999 .

[29]  Janice M. Reichert,et al.  Monoclonal antibodies in the clinic , 2001, Nature Biotechnology.

[30]  Robert Wachbroit,et al.  0The Question Not Asked: The Challenge of Pleiotropic Genetic Tests , 1998, Kennedy Institute of Ethics journal.

[31]  A. Roses,et al.  Pharmacogenetics and future drug development and delivery , 2000, The Lancet.

[32]  Amalia M. Issa,et al.  Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.

[33]  Maureen Hogan Casamayou The Politics of Breast Cancer , 2001 .

[34]  Venter Jc Genomic impact on pharmaceutical development. , 2000 .

[35]  A. Hedgecoe,et al.  Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics , 2003 .

[36]  A. E. Ferentz Integrating pharmacogenomics into drug development. , 2002, Pharmacogenomics.

[37]  J. Trojanowski Tauists, Baptists, Syners, Apostates, and new data , 2002, Annals of neurology.

[38]  J. Kahn,et al.  Pharmacogenetic challenges for the health care system. , 2002, Health affairs.

[39]  M. Gantley,et al.  Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study , 1999, BMJ.

[40]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[41]  L. Fernández-Novoa,et al.  Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. , 1999, Methods and findings in experimental and clinical pharmacology.

[42]  L. Degner,et al.  Relationship between preferences for decisional control and illness information among women with breast cancer: a quantitative and qualitative analysis. , 1994, Social science & medicine.

[43]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[44]  Iona Heath,et al.  Managing Scarcity: Priority Setting and Rationing in the National Health Service , 1997 .

[45]  B. Latour The pasteurization of France , 1988 .

[46]  M. Luca,et al.  ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model , 2002, European Neuropsychopharmacology.

[47]  V. Jelic,et al.  Responder Characteristics to a Single Oral Dose of Cholinesterase Inhibitor: A Double-Blind Placebo-Controlled Study withTacrine in Alzheimer P atients , 2000, Dementia and Geriatric Cognitive Disorders.

[48]  J. Potter,et al.  Pharmacogenetic screening and therapeutic drugs. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[49]  B. Salter The Politics of Change in the Health Service , 1998 .

[50]  Mark A. Rothstein,et al.  Ethical and legal implications of pharmacogenomics , 2001, Nature Reviews Genetics.

[51]  T. Raffin,et al.  Genetic testing and Alzheimer disease: Has the time come? , 1998, Nature Medicine.

[52]  J. Hurst The impact of health economics on health policy in England, and the impact of health policy on health economics, 1972-1997. , 1998, Health economics.

[53]  T. Beauchamp,et al.  Principles of biomedical ethics , 1991 .

[54]  R. Ashcroft Equipoise, knowledge and ethics in clinical research and practice. , 1999, Bioethics.

[55]  F. Boller,et al.  The apolipoprotein E ε4 allele and the response to tacrine therapy in Alzheimer’s disease , 2000, European journal of neurology.

[56]  D. Nebert Pharmacogenetics: 65 candles on the cake , 1997 .

[57]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[58]  R. Frank,et al.  New estimates of drug development costs. , 2003, Journal of health economics.

[59]  F. W. Robertson,et al.  Polymorphism at the Apoprotein‐E locus in relation to risk of coronary disease , 1984, Clinical genetics.

[60]  M. Anglin Working from the inside out: implications of breast cancer activism for biomedical policies and practices. , 1997, Social science & medicine.

[61]  I. Ellis,et al.  HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment. , 2002, Critical reviews in oncology/hematology.

[62]  P. Workman Overview: changing times: developing cancer drugs in genomeland. , 2001, Current opinion in investigational drugs.

[63]  A. Roses,et al.  Apolipoprotein E Genotype: Utility in Clinical Practice in Alzheimer's Disease , 1996, Journal of the American Geriatrics Society.

[64]  G. Siest,et al.  Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses , 2000, Clinical chemistry and laboratory medicine.

[65]  G. Ginsburg,et al.  Personalized medicine: revolutionizing drug discovery and patient care. , 2001, Trends in biotechnology.

[66]  J. Poirier,et al.  Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[67]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M S Wilkes,et al.  Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. , 1999, The Journal of family practice.

[69]  R. Bazell Her-2: the making of herceptin, a revolutionary treatment for breast cancer , 1998 .

[70]  P. Trueman,et al.  ‘Fourth hurdle reviews’, NICE, and database applications , 2001, Pharmacoepidemiology and drug safety.

[71]  J. Law TECHNOLOGY AND HETEROGENEOUS ENGINEERING: THE CASE OF PORTUGUESE EXPANSION , 2018, SCIENCE & TECHNOLOGY STUDIES.

[72]  R. Zussman Sociological Perspectives on Medical Ethics and Decision-Making , 1997 .

[73]  Howard Waitzkin,et al.  The Politics of Medical Encounters: How Patients and Doctors Deal With Social Problems , 1991 .

[74]  John D. W. Guice,et al.  Designing the future: the culture of new trends in science and technology , 1999 .

[75]  O. Corrigan,et al.  A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. , 2002, Social science & medicine.

[76]  M. Ingelman-Sundberg Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001, Journal of internal medicine.

[77]  J. Leon,et al.  Pharmacogenomic testing: the cost factor , 2001, The Pharmacogenomics Journal.

[78]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[79]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[80]  J Emery,et al.  The challenge of integrating genetic medicine into primary care , 2001, BMJ : British Medical Journal.

[81]  G. Oberhuber,et al.  Is fluorescence in situ hybridization really superior to HercepTest? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R M. Norton,et al.  Clinical pharmacogenomics: applications in pharmaceutical R&D. , 2001, Drug discovery today.

[83]  T. P. Hughes Networks of power : electrification in Western society, 1880-1930 , 1984 .

[84]  J. Kurth Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk , 2000 .

[85]  C. Møldrup Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review , 2002, Public Health Genomics.

[86]  W. Sadee's Pharmacogenomics. Interview by Clare Thompson. , 1999, BMJ.

[87]  A. Roses,et al.  Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease , 1997, Annals of neurology.

[88]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[89]  S. Kumar Resisting revolution: generalism and the new genetics , 1999, The Lancet.

[90]  M. Boyce-Jacino,et al.  A SNPshot: pharmacogenetics and the future of drug therapy. , 2000, Trends in biotechnology.

[91]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[92]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[93]  M. Press,et al.  The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. , 1999, Seminars in oncology.

[94]  H. Leufkens,et al.  The interface between pharmacoepidemiology and pharmacogenetics. , 2000, European journal of pharmacology.

[95]  T. Pang,et al.  Genomics and global health , 2002, BMJ : British Medical Journal.

[96]  J. Abraham Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation , 1995 .

[97]  N. Herrmann,et al.  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. , 2003, Journal of psychiatry & neuroscience : JPN.

[98]  Susan Leigh Star,et al.  Changing Order: Replication and Induction in Scientific Practice by H. M. Collins (review) , 1988, Technology and Culture.

[99]  R. Anspach,et al.  Deciding Who Lives: Fateful Choices in the Intensive-Care Nursery , 1993 .

[100]  Harold Maurice Collins,et al.  Tantalus and the Aliens: , 1999 .

[101]  J Hutton,et al.  A nice challenge for health economics. , 2000, Health economics.

[102]  J. Olson,et al.  Bathsheba’s Breast: Women, Cancer and History , 2004, Nursing History Review.

[103]  D. Rosenstein,et al.  Clinical Research and the PhysicianPatient Relationship , 2003, Annals of Internal Medicine.

[104]  J. Benbassat,et al.  Patients' preferences for participation in clinical decision making: a review of published surveys. , 1998, Behavioral medicine.

[105]  Butler Rn ApoE: new risk factor for Alzheimer's. , 1994 .

[106]  P. Joubert,et al.  Opportunities and strategies for introducing pharmacogenetics into early drug development. , 2001, Drug discovery today.

[107]  Donald MacKenzie The Certainty Trough , 1998 .

[108]  R. Zussman Intensive Care: Medical Ethics and the Medical Profession , 1992 .

[109]  F. Roberts Talking About Treatment: Recommendations for Breast Cancer Adjuvant Treatment , 1999 .

[110]  I. Ellis,et al.  Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.

[111]  A. Marshall,et al.  Laying the foundations for personalized medicines , 1997, Nature Biotechnology.

[112]  S. Liggett Pharmacogenetic applications of the Human Genome project , 2001, Nature Medicine.

[113]  E. Jazwinska Exploiting human genetic variation in drug discovery and development. , 2001, Drug discovery today.

[114]  E. Ferlie,et al.  Calman-Hine reassessed: a survey of cancer network development in England, 1999-2000. , 2002, Journal of evaluation in clinical practice.

[115]  R. Weinshilboum The genomic revolution and medicine. , 2002, Mayo Clinic proceedings.

[116]  L. Grimaldi,et al.  Pharmacogenomics of neurodegenerative diseases. , 2001, European journal of pharmacology.

[117]  E. Einsiedel,et al.  Consensus Conferences as Deliberative Democracy , 2000 .

[118]  G. Frisoni Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice , 2001, Journal of Neurology.

[119]  M D Rawlins,et al.  The failings of NICE , 2001, BMJ : British Medical Journal.

[120]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[121]  Richard Smith,et al.  The failings of NICE , 2000, BMJ : British Medical Journal.

[122]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  J Marx New Alzheimer's theory stirs controversy. , 1993, Science.

[124]  W. Kalow Pharmacogenetics: Past and future , 1990 .

[125]  S. Miles,et al.  Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors. , 1999, JAMA.

[126]  S. Lovestone,et al.  UK Alzheimer's Disease Genetics Consortium , 1999, International journal of geriatric psychiatry.

[127]  C. Bosk Obtaining Voluntary Consent for Research in Desperately Ill Patients , 2002, Medical care.

[128]  Simon Lovestone,et al.  Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.

[129]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[130]  G. Tsongalis,et al.  Pharmacogenomics: will it change the field of medicine? , 2001, Clinica chimica acta; international journal of clinical chemistry.

[131]  A. Roses,et al.  Pharmacogenetics place in modern medical science and practice. , 2002, Life sciences.

[132]  Maren Klawiter Racing for the Cure, Walking Women, and Toxic Touring: Mapping Cultures of Action within the Bay Area Terrain of Breast Cancer , 1999 .

[133]  N. Cutler,et al.  Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease , 1999, The Annals of pharmacotherapy.

[134]  D. Hughes,et al.  "Ruling in" and "ruling out": two approaches to the micro-rationing of health care. , 1997, Social science & medicine.

[135]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.

[136]  N. Relkin,et al.  The National Institute on Aging/Alzheimer's Association Recommendations on the Application of Apolipoprotein E Genotyping to Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[137]  J. Baselga Clinical trials of Herceptin(trastuzumab). , 2001, European journal of cancer.

[138]  H. Wiseman Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention , 1994 .

[139]  Paul S. Appelbaum,et al.  Informed Consent: Legal Theory and Clinical Practice , 1987 .

[140]  T. Bird Apolipoprotein E genotyping in the diagnosis of alzheimer's disease: A cautionary view , 1995, Annals of neurology.

[141]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[142]  Julie A. Johnson,et al.  Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. , 2002, Trends in Molecular Medicine.

[143]  G. Sanders,et al.  Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. , 1999, Genetic testing.

[144]  L. Fernández-Novoa,et al.  Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. , 2000, Drugs of today.

[145]  J. Growdon Apolipoprotein E and Alzheimer disease. , 1998, Archives of Neurology.

[146]  Harry Greenberg,et al.  Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study. , 2002, Controlled clinical trials.

[147]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[148]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[149]  M. Piccart,et al.  An overview of HER2. , 2001, Seminars in oncology.

[150]  K. Lindpaintner The importance of being modest--reflections on the pharmacogenetics of abacavir. , 2002, Pharmacogenomics.

[151]  David Housman,et al.  Why pharmacogenomics? Why now? , 1998, Nature Biotechnology.

[152]  S. Shak Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.

[153]  A. Barry Political Machines: Governing a Technological Society , 2001 .

[154]  B. Gomez-Mancilla,et al.  Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group , 2002, The Pharmacogenomics Journal.

[155]  M. Fortun Mediated speculations in the genomics futures markets , 2001 .

[156]  U. Meyer Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[157]  K. Lackner,et al.  Pharmacogenomics: implications for laboratory medicine. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[158]  John A. Robertson,et al.  Consent and privacy in pharmacogenetic testing , 2001, Nature Genetics.

[159]  P. Amouyel,et al.  APOE genotyping and response to drug treatment in Alzheimer's disease , 1997, The Lancet.

[160]  Alberto Cambrosio,et al.  Exquisite Specificity: The Monoclonal Antibody Revolution , 1995 .

[161]  J. Poirier Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[162]  S. Frantz,et al.  New drug approvals for 2002 , 2003, Nature Reviews Drug Discovery.

[163]  J. Poirier,et al.  Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease , 1998, Neurology.

[164]  G. Banna,et al.  BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. , 2001, Cancer treatment reviews.

[165]  F. Mullan,et al.  The town meeting for technology. The maturation of consensus conferences. , 1985, JAMA.

[166]  G. Hortobagyi,et al.  Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. , 2001, Seminars in oncology.

[167]  B. Wynne,et al.  Misunderstanding science? : the public reconstruction of science and technology , 1996 .

[168]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  R. C. Fox,et al.  Medical Morality Is Not Bioethics—Medical Ethics in China and the United States , 2015, Perspectives in biology and medicine.

[170]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[171]  Marc Berg,et al.  The practice of medical technology. , 2003, Sociology of health & illness.

[172]  C. McNeil Herceptin raises its sights beyond advanced breast cancer. , 1998, Journal of the National Cancer Institute.

[173]  D C McCrory,et al.  Empirical research on informed consent. An annotated bibliography. , 1999, The Hastings Center report.

[174]  C. Caldas,et al.  Impact of genomics on drug discovery and clinical medicine. , 2000, QJM : monthly journal of the Association of Physicians.

[175]  J. Aerssens Pharmacogenomic approaches in Alzheimer's disease drug development , 2002 .

[176]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[177]  B. Kakulas,et al.  Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: A cautionary view , 1995, Annals of neurology.

[178]  R. Rapp Testing women, testing the fetus , 1999 .

[179]  N. Relkin,et al.  Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.

[180]  Reinhart Koselleck,et al.  Futures Past: On the Semantics of Historical Time , 1985 .

[181]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[182]  Patricia L. Marshall,et al.  The Decision Dynamics of Clinical Research: The Context and Process of Informed Consent , 2002, Medical care.

[183]  A D Roses,et al.  Apolipoprotein E and Alzheimer's Disease A Rapidly Expanding Field with Medical and Epidemiological Consequences , 1996, Annals of the New York Academy of Sciences.

[184]  G. Hortobagyi,et al.  Ongoing and planned adjuvant trials with trastuzumab. , 2000, Seminars in Oncology.

[185]  Michael Doherty,et al.  Pharmacogenetics--legal, ethical and regulatory considerations. , 2001, Pharmacogenomics.

[186]  R. Bullock New drugs for Alzheimer's disease and other dementias , 2002, British Journal of Psychiatry.

[187]  R. Macklin Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine , 1999 .

[188]  M. H. Ensom,et al.  Pharmacogenetics , 2001, Clinical pharmacokinetics.

[189]  H. Paulson Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. , 2002, Neurologic clinics.

[190]  M Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[191]  S. Schnitt,et al.  Current status of HER2 testing: caught between a rock and a hard place. , 2001, American journal of clinical pathology.

[192]  S. Lovestone,et al.  Consensus Statement on Predictive Testing for Alzheimer Disease , 1995, Alzheimer disease and associated disorders.

[193]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[194]  C. Sinding Literary Genres and the Construction of Knowledge in Biology: Semantic Shifts and Scientific Change , 1996 .

[195]  B. Latour Science in action : how to follow scientists and engineers through society , 1989 .

[196]  W. A. Gool The Use of Apolipoprotein E Genotyping as a Diagnostic Test in Suspected Alzheimer's Disease , 1996 .

[197]  Jordan Goodman,et al.  The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug , 2001 .

[198]  Robertson Js,et al.  Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000 .

[199]  R. Klein The politics of the National Health Service , 1983 .

[200]  K S Kosik,et al.  Public attitudes about genetic testing for Alzheimer's disease. , 2001, Health affairs.

[201]  A D Roses,et al.  The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. , 2000, Biochimica et biophysica acta.

[202]  C. Freeman Economics of Industrial Innovation , 1975 .

[203]  I. Varekamp,et al.  Age rationing for renal transplantation? The role of age in decisions regarding scarce life extending medical resources. , 1998, Social science & medicine.

[204]  B. Leyland-Jones Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[205]  K. Taylor,et al.  Integrating conflicting professional roles: physician participation in randomized clinical trials. , 1992, Social science & medicine.

[206]  K. Lindpaintner Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases. , 1999, British medical bulletin.

[207]  S. Wiley Genomics in the real world. , 1998, Current pharmaceutical design.

[208]  A. Marshall,et al.  Getting the right drug into the right patient , 1997, Nature Biotechnology.

[209]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.

[210]  G. Wilcock,et al.  Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease , 1998, International journal of geriatric psychiatry.

[211]  L. Bracco,et al.  Pharmacogenomics and Personalised Medicine , 2002 .

[212]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[213]  A Regalado,et al.  Inventing the pharmacogenomics business. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[214]  A. Roses Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[215]  P. Oestreicher 4th Annual Pharmacogenomics and Medicine Lectures. , 2001, Pharmacogenomics.

[216]  Paul Martin,et al.  The Drugs Don't Work , 2003, Social studies of science.

[217]  N. Greig,et al.  Current drug targets for Alzheimer's disease treatment , 2002 .

[218]  C. Newdick Who Should We Treat?: Law, Patients and Resources in the NHS , 1995 .

[219]  David H. Guston,et al.  Evaluating the First U.S. Consensus Conference: The Impact of the Citizens’ Panel on Telecommunications and the Future of Democracy , 1999 .

[220]  A. Roses Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease , 1995, Annals of neurology.

[221]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[222]  P. Workman Scoring a bull's-eye against cancer genome targets. , 2001, Current opinion in pharmacology.

[223]  S. Lovestone Genetics consortiums can offer views facilitating best practice in Alzheimer's disease , 1998, BMJ.

[224]  R. March Pharmacogenomics: The Genomics of Drug Response , 2000, Yeast.

[225]  A. Gafni,et al.  On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.

[226]  S. Batt Patient No More, the Politics of Breast Cancer , 1994 .

[227]  U. A. Meyers Molecular genetics and the future of pharmacogenetics , 1990 .

[228]  R. Chadwick Criteria for genetic screening: the impact of pharmaceutical research , 1999 .

[229]  A. Roses Pharmacogenetics and the practice of medicine , 2000, Nature.

[230]  N. Dracopoli,et al.  Applied genomics: integration of the technology within pharmaceutical research and development. , 2000, Current opinion in biotechnology.

[231]  Utilization of new technologies in drug trials and discovery. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[232]  M. Hung,et al.  Role of erbB2 in breast cancer chemosensitivity. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[233]  M. Pericak-Vance,et al.  Clinical application of apolipoprotein E genotyping to Alzheimer's disease , 1994, The Lancet.

[234]  A. Relman Tacrine as a Treatment for Alzheimer's Dementia , 1991 .

[235]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[236]  Mace L. Rothenberg,et al.  Improving the evaluation of new cancer treatments: challenges and opportunities , 2003, Nature Reviews Cancer.

[237]  Arie Rip,et al.  The Rise of Membrane Technology , 1998 .

[238]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[239]  K. Fox,et al.  Thrombolytic treatment for elderly patients. , 1992, BMJ.

[240]  R. Westrum The Social Construction of Technological Systems , 1989 .

[241]  R. Walker The failings of NICE. "Spinning" is not nice. , 2001, BMJ.

[242]  David H. DeVorkin,et al.  Inventing Accuracy: A Historical Sociology of Nuclear Missile Guidance , 1990 .

[243]  A. Issa,et al.  Apolipoprotein E Genotyping for Pharmacogenetic Purposes in Alzheimer's Disease: Emerging Ethical Issues , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[244]  P. Littlejohns,et al.  The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence. , 2003, The Lancet. Oncology.

[245]  P. Tariot,et al.  Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. , 1987, The New England journal of medicine.

[246]  A. Roses,et al.  Prediction for unimpaired subjects is different from diagnosis of demented patients , 1997, Annals of neurology.

[247]  B. Freedman Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.

[248]  B. Rothman Genetic Maps and Human Imaginations: The Limits of Science in Understanding Who We Are , 1998 .

[249]  A. Roses,et al.  The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.

[250]  M. Pericak-Vance,et al.  Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease , 1996, The Lancet.

[251]  R. Kisabeth,et al.  Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. , 2001, Mayo Clinic proceedings.

[252]  S. DeKosky,et al.  Apolipoprotein E genotyping in the diagnosis of alzheimer's disease , 1995 .

[253]  H. Sakul,et al.  Chapter 23. Pharmacogenomics , 2000 .

[254]  R. Woodman Storage of human organs prompts three inquiries , 2000, BMJ : British Medical Journal.

[255]  H. Hoyme,et al.  Pharmacogenomics: the future of drug therapy , 2002, Clinical genetics.

[256]  Pharmacogenetics: the ethical context , 2001, The Pharmacogenomics Journal.

[257]  From the lab to the clinic: integration of pharmacogenics into clinical development. , 2002, Pharmacogenomics.

[258]  E. Vesell,et al.  Genetic Variation as a Guide to Drug Development , 1998, Science.

[259]  K. Blennow,et al.  Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype , 2001, Journal of Neural Transmission.

[260]  S. Akhtar Pharmacogenomics: Are pharmacists ready for genotyped prescribing? , 2002 .

[261]  P. Amouyel,et al.  Genetic susceptibility factors for Alzheimer's disease. , 2001, European journal of pharmacology.

[262]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[263]  A Whitehead,et al.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. , 1998, JAMA.

[264]  K. Mokbel,et al.  From HER2 to Herceptin , 2001, Current medical research and opinion.

[265]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[266]  L. Vaszar,et al.  Pharmacogenomics and the challenge to privacy , 2002, The Pharmacogenomics Journal.

[267]  S Galloway,et al.  Information needs of women during early treatment for breast cancer. , 1997, Journal of advanced nursing.

[268]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[269]  Amalia M. Issa,et al.  Ethical considerations in clinical pharmacogenomics research. , 2000, Trends in pharmacological sciences.

[270]  Eduardo Bruera,et al.  Treatment decisions for breast carcinoma , 2002, Cancer.

[271]  S. Post On Not Jumping the Gun: Ethical Aspects of APOE Gene Testing for Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[272]  T. Pinch,et al.  The Social Construction of Facts and Artefacts: or How the Sociology of Science and the Sociology of Technology might Benefit Each Other , 1984 .

[273]  M. Bleavins,et al.  Pharmacogenetic application in drug development and clinical trials. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[274]  Kathleen Jordan,et al.  The Dissemination, Standardization and Routinization of a Molecular Biological Technique , 1998 .

[275]  L. Furness,et al.  Pharmacogenomics - it's not just pharmacogenetics. , 1998, Current opinion in biotechnology.

[276]  W. Weber,et al.  The legacy of pharmacogenetics and potential applications. , 2001, Mutation research.

[277]  W. Haseltine Not quite pharmacogenomics , 1998, Nature Biotechnology.

[278]  D. Miles Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting , 2001, Breast cancer research : BCR.

[279]  A. Roses SNPs—where's the beef? , 2002, The Pharmacogenomics Journal.

[280]  Ferguson Jh The NIH Consensus Development Program. The evolution of guidelines. , 1996 .

[281]  Greg Myers,et al.  Writing biology : texts in the social construction of scientific knowledge , 1990 .

[282]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[283]  S. Humphries,et al.  Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.

[284]  Simon Joss,et al.  Participatory technology assessment: European perspectives , 2002 .

[285]  B. Lerner,et al.  The Breast Cancer Wars: Hope, Fear, and the Pursuit of a Cure in Twentieth Century America , 2004, Nursing History Review.